Merck & Company, Inc.$128.97JNJ · NYSE
| FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B |
| Cost of Revenue | $30.26B | $27.47B | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B | $27.09B |
| Gross Profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B |
| Research & Development | $109.00M | $1.84B | $483.00M | $0.00 | $0.00 | — | — | — |
| Selling, General & Administrative | $23.68B | $22.87B | $21.51B | $20.25B | $20.12B | $22.08B | $22.18B | $22.54B |
| Interest Expense | — | — | $772.00M | $276.00M | $183.00M | $201.00M | $318.00M | $1.00B |
| Other Income / (Expense) | $7.21B | -$4.69B | -$6.63B | -$810.00M | -$526.00M | -$2.90B | -$2.52B | -$1.41B |
| Income Before Taxes | $32.58B | $16.69B | $15.06B | $19.36B | $19.18B | $16.50B | $17.33B | $18.00B |
| Provision for Income Taxes | $5.78B | $2.62B | $1.74B | $2.99B | $1.38B | $1.78B | $2.21B | $2.70B |
| Net Income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B |
| Basic EPS | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 |
| Diluted EPS | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 |
| Basic Shares Outstanding | 2.41B | 2.41B | 2.53B | 2.63B | 2.63B | 2.63B | 2.65B | 2.68B |
| Diluted Shares Outstanding | 2.43B | 2.43B | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $11.69 | $11.60 | $11.89 | 8 | ↑8 ↓0 |
| Dec 2027 | $12.81 | $12.25 | $13.54 | 9 | ↑8 ↓0 |
| Dec 2028 | $14.27 | $13.37 | $15.43 | 4 | ↑4 ↓0 |
| Dec 2029 | $14.67 | $14.61 | $14.73 | 2 | ↑2 ↓0 |
